-
Product Insights
NewLow Affinity Immunoglobulin Gamma Fc Region Receptor III A – Drugs In Development, 2024
The Low Affinity Immunoglobulin Gamma Fc Region Receptor III A pipeline drugs market research report outlays comprehensive information on the Low Affinity Immunoglobulin Gamma Fc Region Receptor III A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology which include indications of Solid Tumor, and Unspecified Cancer. It also reviews key players involved in Low Affinity Immunoglobulin...
-
Product Insights
NewLow Affinity Immunoglobulin Gamma Fc Region Receptor II-b – Drugs In Development, 2024
The Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b pipeline drugs market research report outlays comprehensive information on the Low Affinity Immunoglobulin Gamma Fc Region Receptor II-b targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Immunology, Oncology, Undisclosed, and Respiratory which include indications of Autoimmune Disorders, Systemic Lupus Erythematosus, Solid Tumor, Lymphoma, Unspecified, and Allergic Asthma. It...
-
Product Insights
NewFc Fragment Of IgG Low Affinity III Receptor – Drugs In Development, 2024
The Fc Fragment Of IgG Low Affinity III Receptor pipeline drugs market research report outlays comprehensive information on the Fc Fragment Of IgG Low Affinity III Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Infectious Disease, and Immunology which include indications of Solid Tumor, Non-Small Cell Lung Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Hepatitis...
-
Thematic Analysis
NewCybersecurity in Sport – Thematic Intelligence
Cybersecurity in Sport Thematic Intelligence Report Overview The business of sport naturally accrues a large amount of sensitive data. Sports teams, federations, broadcasters, and sponsors are all vulnerable to attacks due to their significant revenues, the exposure any attack will receive, and the multiple entry points that result from their distributed communications. Events and international bodies provide a global stage for hackers. Nation-state-sponsored attacks have occurred in the sports industry, usually in response to regulations and sanctions against countries and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XmAb-662 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XmAb-662 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XmAb-662 in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XmAb-662 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FS-120 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FS-120 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FS-120 in Solid Tumor Drug Details: FS-120 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOS-342 in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOS-342 in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOS-342 in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: PRS-342...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOS-342 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BOS-342 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BOS-342 in Solid Tumor Drug Details: PRS-342 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XmAb-662 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XmAb-662 in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XmAb-662 in Cervical Cancer Drug Details: Xmab-662 is under development for...